New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
11:46 EDTVNDA, OLED, ICPT, RPTP, RAX, UBNT, CALL, GOGO, MNKD, ARWROptions with decreasing implied volatility
Options with decreasing implied volatility: RPTP ARWR CALL ICPT MNKD UBNT OLED GOGO RAX UVXY VNDA
News For RPTP;ARWR;CALL;ICPT;MNKD;UBNT;OLED;GOGO;RAX;VNDA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 26, 2015
16:53 EDTUBNTUbiquiti Networks initiated with a Neutral at Guggenheim
15:07 EDTICPTIntercept's FLINT data more convincing than Gefit data, says RBC Capital
Subscribe for More Information
14:45 EDTICPTIntercept's risk/reward remains favorable, says Citigroup
Subscribe for More Information
13:04 EDTICPTIntercept rallies after GENFIT announces NASH study results
GENFIT announced topline results of the phase 2 GOLDEN-505 trial in NASH. It stated, "Due to the unexpected rate of resolution of NASH in patients randomized to placebo who had early NASH (NAS of 3, placebo response rate>57%), along with the high number of sites for a limited sample size, the study as initially designed did not enable the trial to meet directly the primary endpoint. With correction for this baseline severity and site heterogeneity by a standardized statistical analysis, GFT505 120mg meets the primary endpoint: Reversal on NASH without worsening of fibrosis, as detailed below." Treatment with GFT505 provides a significant beneficial effect on the primary endpoint in the global randomized population, where patients without an end of treatment biopsy were considered as non-responders, GENFIT added. The primary endpoint was also achieved in the evaluable population of patients who underwent both baseline and end of study liver biopsies. Shares of Intercept, which is also developing a NASH treatment, jumped 7%, or $18.06 to $278.70.
12:56 EDTICPTIntercept jumps after Genfit says NASH drug missed endpoint in Phase 2 study
Subscribe for More Information
10:04 EDTUBNTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:36 EDTUBNTUbiquiti Networks downgraded to Neutral from Outperform at Macquarie
Subscribe for More Information
March 25, 2015
16:55 EDTICPTOrbiMed Advisors lowers stake in Intercept to 5.64% from 7.0%
March 24, 2015
10:24 EDTGOGOGogo CAO Thomas McShane to resign
In a regulatory filing, Gogo reports that on March 20, Thomas McShane notified the company and its board that he plans to resign from his current positions as VP, controller and Chief Accounting Officer for personal reasons. McShane will remain to assist with the search for his successor and to allow for a transition of his responsibilities. The company has initiated a search to identify a CAO. McShane’s resignation effective date will depend on the date a successor is identified and the transition period required once a successor is fully engaged.
10:15 EDTRPTPRaptor Pharmaceuticals management to meet with Leerink
Subscribe for More Information
09:41 EDTGOGOGogo estimates lowered further at Morgan Stanley
Subscribe for More Information
05:46 EDTMNKDStocks with implied volatility movement; AMZN MNKD
Subscribe for More Information
March 23, 2015
07:22 EDTICPTIntercept price target raised to $265 from $205 at Leerink
Subscribe for More Information
March 20, 2015
16:00 EDTMNKDOptions Update; March 20, 2015
Subscribe for More Information
09:28 EDTGOGOGogo management to meet with JPMorgan
Subscribe for More Information
09:24 EDTICPTOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Ctrip.com (CTRP), up 20.1%... Rally Software (RALY), up 17.3%... Nike (NKE), up 5.2%... Darden Restaurants (DRI), up 4.3%... Cheetah Mobile (CMCM), up 3.6%. ALSO HIGHER: Prothena (PRTA), up 40.2% after reporting positive results from Phase 1 study of PRX002... Viggle (VGGL), up 26.9% after confirming receipt of offer from chairman and CEO Robert Sillerman... Intercept Pharmaceuticals (ICPT), up 8.5% after announcing new data analyses from FLINT trial... Biogen Idec (BIIB), up 9.7% after presenting positive interim results from study of aducanumab... Pier 1 Imports (PIR), up 5.2% after being upgraded to Outperform from Perform at Oppenheimer... JinkoSolar (JKS), up 2.8% after announcing that it will supply 75 MWdc of its PV solar modules to Red Horse 2 project and following a strategic collaboration agreement with DuPont (DD). DuPont is up just under 1%. DOWN AFTER EARNINGS: AK Steel (AKS), down 6.8%... Youku Tudou (YOKU), down 4.9%... Tiffany (TIF), down 3.3%. ALSO LOWER: Macerich (MAC), down 7.7% after Simon makes $95.50 per share "best and final" offer.
06:02 EDTICPTIntercept announces new data analyses from FLINT trial
Subscribe for More Information
March 19, 2015
13:07 EDTICPTIntercept to host analyst and investor meeting
Subscribe for More Information
March 18, 2015
09:32 EDTMNKDMannKind faces cash shortfall if $100M debt not settled, TheStreet says
Subscribe for More Information
09:00 EDTICPTIntercept price target raised to $344 from $258 at RW Baird
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use